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a  b  s  t  r  a  c  t
Obesity  is  a risk  factor  for various  cardiovascular  diseases  including  hypertension,  atherosclerosis,  and
myocardial  infarction.  Recent  studies  aimed  at understanding  the  microenvironment  of adipose  tissue
and its impact  on  systemic  metabolism  have  shed  light  on  the  pathogenesis  of obesity-linked  cardiovascu-
lar  diseases.  Adipose  tissue  functions  as an endocrine  organ  by secreting  multiple  immune-modulatoryeywords:
ardiovascular disease
diponectin
frp5
eptin
NF
proteins  known  as adipokines.  Obesity  leads  to  increased  expression  of  pro-inﬂammatory  adipokines
and  diminished  expression  of  anti-inﬂammatory  adipokines,  resulting  in  the  development  of  a  chronic,
low-grade  inﬂammatory  state.  This  adipokine  imbalance  is  thought  to  be a key  event in  promoting  both
systemic  metabolic  dysfunction  and  cardiovascular  disease.  This  review  will  focus  on  the  adipose  tis-
sue  microenvironment  and  the  role of  adipokines  in  modulating  systemic  inﬂammatory  responses  that
contribute  to cardiovascular  disease.© 2013  Japanese  College  of  Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.
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ntroduction
Obesity and associated metabolic disorders are becoming major
ealth care concerns around the world. It is estimated that over
0% of adults and 30% of children are overweight in the USA, and if
rends continue more than 50% of the world’s adult population will
e overweight in a few decades [1–3]. Obesity and its comorbidities
ave a devastating effect on vascular function and create conditions
production in the adipose tissue of pro- and anti-inﬂammatory
cytokines, referred to as adipokines, which contribute to the devel-
opment of metabolic and cardiovascular diseases.
Obesity-induced changes in adipose tissue
microenvironment
To understand how obesity has an impact on cardiovascular
hat favor cardiovascular disease. Obesity promotes cardiovascular
isease via many mechanisms including ectopic lipid deposition,
yperglycemia, and the development of a procoagulant state, to
ame a few. This review will focus on how obesity inﬂuences the
∗ Corresponding author at: Boston University Medical Campus, 715 Albany Street,
611, Boston, MA  02118, USA. Tel.: +1 617 414 2390; fax: +1 617 414 2391.
E-mail address: kxwalsh@bu.edu (K. Walsh).
914-5087/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2013.11.006function, it is important to ﬁrst focus on obesity-induced changes
in the microenvironment of adipose tissue (Fig. 1). The excess of
caloric intake leads to an expansion of the adipose tissue that
is initially driven by an increase in the number of adipocytes
(adipocyte hyperplasia) mediated by the recruitment and prolifer-
ation of adipogenic progenitors [4–7]. This hyperplastic response is
severely blunted with age [8], so the sustained exposure to exces-
sive energy intake ultimately leads to an increase in adipocyte size
(adipocyte hypertrophy) that compromises the functionality of the
vier Ltd. All rights reserved.
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Fig. 1. Obesity-linked changes in adipose tissue composition. Obesity can promote changes in adipose tissue and promote the transition to a metabolically dysfunctional
phenotype. As the body develops obesity, adipocytes undergo hypertrophy due to the increased storage of triglycerides. Macrophages in lean fat express markers of a M2
or  “alternatively activated” state, whereas obesity leads to recruitment and accumulation of a M1 or “classically activated” state with macrophages and CD8+ T cells in
adipose  tissue. Metabolically dysfunctional adipose tissue is indicated by the presence of crown-like histological structures that represent activated M1-like macrophages
surrounding a necrotic adipocyte and CD4+ T cells. Anti-inﬂammatory adipokines, such as adiponectin are preferentially produced by lean adipose tissue, whereas high levels
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dipose tissue [6,9]. In advanced obesity, lipid-laden hypertrophied
dipocytes undergo necrotic and/or apoptotic cell death, contribut-
ng to the recruitment of inﬂammatory cells and to adipose tissue
ysfunction [10–12].
Whereas adipose tissue is mainly composed of adipocytes, other
ell types, including lymphocytes, macrophages, ﬁbroblasts, and
ascular cells, also appear to have important roles in controlling
he functional status of this tissue. Obesity leads to major changes
n the cellular composition of adipose tissue and also modulates the
henotype of individual cells within this tissue. For example, adi-
ose tissue from obese organisms is inﬁltrated by a large number
f macrophages, leading to increases in both absolute macrophage
umber and the relative level of macrophage-to-adipocyte ratio.
acrophage recruitment to adipose tissue is associated with sys-
emic inﬂammation and insulin resistance [13,14]. In addition
o this quantitative change, the macrophage phenotype is also
ltered by the obese state. The M1/M2  concept is a convenient
eans for classifying the inﬂammatory status of the macrophage.
acrophages that accumulate in adipose tissue of obese organisms
end to express genes associated with a M1-like or “classically acti-
ated” phenotype. In contrast, adipose tissue macrophages from
ean organisms tend to express genes associated with a M2-like
r “alternatively activated” phenotype [15]. Stimulation with T
elper 1 (TH1)-type cytokines, including interferon-, or bacterial
roducts will promote the M1-like phenotype in macrophages. M1
acrophages produce pro-inﬂammatory cytokines, such as tumor
ecrosis factor (TNF), express inducible nitric oxide synthase
iNOS), and produce high levels of reactive oxygen and nitrogen
ntermediates [16]. This class of macrophages is typically associ-
ted with inﬂammation and tissue destruction. On the other hand,
2-like macrophages preferentially express anti-inﬂammatory
ytokines, such as interleukin (IL)-10, and the enzyme arginase-
, which inhibits iNOS activity. These types of macrophages tend
o be associated with wound healing, angiogenesis, and the resolu-
ion of inﬂammation [16]. It is believed that M1-like macrophages
romote insulin resistance, whereas M2-like macrophages protectagainst obesity-induced insulin resistance [17]. Supporting this
notion, ablation of CD11c-positive, M1-like macrophages normal-
izes insulin sensitivity in obese mice [18].
Another distinctive feature of adipose tissue from obese orga-
nisms is the presence of “crown-like” structures in histological
sections. These features represent macrophages that surround dead
or dying adipocytes [10,11]. Obese subjects lacking crown-like
structures exhibit better metabolic control, diminished inﬂamma-
tory gene expression, and reduced cardiovascular risk than body
mass-matched individuals who display this histological feature
[19]. On the other hand, the number of crown-like structures in adi-
pose tissue is correlated with inﬂammation and insulin resistance
in metabolic syndrome patients [10,19]. Typically macrophages
function to rapidly remove dead cell debris prior to the disrup-
tion of their membranes. Thus, it is tempting to speculate that
the presence of crown-like structures signiﬁes a breakdown in the
phagocytic process in adipose tissue, thereby exacerbating the pro-
inﬂammatory state.
Obesity also inﬂuences the subsets of T cells that are present in
adipose tissue, where they appear to function in the regulation of
macrophage phenotype. CD4+ regulatory T cells and TH2-polarized
cells are found in higher abundance in the adipose tissue of lean
mice, and these cells contribute to the maintenance of adipose tis-
sue function and insulin sensitivity, in part through promoting an
anti-inﬂammatory alternative activation of macrophages [20,21].
On the other hand, under conditions of obesity, the accumulation
of CD8+ effector T cells and CD4+ TH1 cells in the adipose tissue
will generate TH1 signals and initiate the recruitment and activa-
tion of macrophages, perpetuating the pro-inﬂammatory cascade
that is associated with insulin resistance [21,22]. Thus, obesity-
induced alterations in the balance of TH1- and TH2-type signals
are likely to inﬂuence macrophage recruitment and phenotype in
adipose tissue, thereby generating either a pathogenic or a pro-
tective environment. B cells also appear to have a pivotal role
in obesity-induced adipose tissue inﬂammation, promoting T cell
and macrophage activation and contributing to insulin resistance
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23]. Similarly, mast cells have been reported to accumulate in
bese adipose tissue before the appearance of macrophages, and
tudies in mast-cell deﬁcient mice suggest a role for this cell-type
n obesity-associated metabolic dysfunction [24]. Neutrophil inﬁl-
ration and activation also contributes to adipose tissue dysfunction
hrough the action of neutrophil elastase [25,26]. Finally, it has
een reported that eosinophils in adipose tissue promote alterna-
ive activation of macrophages and glucose tolerance through the
roduction of the TH2 cytokine IL-4 [27]. Therefore, the status of
mmune cells in adipose tissue is an area of intense investigation,
nd a better understanding of the interplay between inﬂammation
nd metabolism is warranted.
Of particular relevance to the subject of this review, a num-
er of provocative studies have made the case that obesity is also
ssociated with changes in vascular structure and function within
dipose tissue. Several studies in patients and animal models have
hown that obesity causes capillary rarefaction in adipose tissue,
nd this leads to localized hypoxia [28–31]. In contrast with these
tudies, a recent report showed that obese human subjects display
ncreased rather than decreased oxygen tension in adipose tissue,
espite reduced adipose tissue blood ﬂow [32]. However, it must
e noted that, while suggesting an overall hyperoxic state, this lat-
er study does not rule out the possibility of localized hypoxic areas
ithin adipose tissue, and therefore further studies are required in
his ﬁeld. Regardless, the various studies coincide in their ﬁndings
f decreased adipose tissue capillarization, which may  limit nutri-
nt delivery and contribute to insulin resistance. Alternatively, this
ascular dysfunction could contribute to adipose tissue inﬂamma-
ion by promoting ischemia-induced adipocyte necrosis, followed
y macrophage recruitment and activation. Recent studies with
enetically engineered mice have provided conclusive evidence
f the role of adipose tissue vascularization in obesity-associated
etabolic dysfunction. Experiments with mice overexpressing vas-
ular endothelial growth factor A (VEGF-A) in adipocytes show that
ncreased VEGF-mediated angiogenesis in white adipose tissue can
ttenuate some of the metabolic effects of diet-induced obesity,
uch as insulin resistance and hepatic steatosis [33–35]. Conversely,
dipocyte-restricted deletion of VEGF-A results in scarce adipose
issue vascularization, which leads to increased adipose tissue
nﬂammation and systemic insulin resistance and glucose intol-
rance, as well as hepatic steatosis [35]. Furthermore, it has been
eported that hypoxia-inducible factor 1 (HIF1) – a master regu-
ator of VEGF expression – is upregulated during obesity-associated
dipose tissue expansion [36]. Interestingly, various experiments in
enetically engineered mice suggest that HIF1 does not inﬂuence
dipose tissue capillarization, but promotes adipose tissue expan-
ion, inﬂammation, and ﬁbrosis, leading to systemic metabolic
ysfunction [37–40].
The phenotypic changes in adipose tissue that result from obe-
ity are also thought to induce vascular endothelial cell activation.
ecause activated endothelial cells express adhesion molecules and
hemotactic factors that contribute to the recruitment of inﬂam-
atory cells, it is reasonable to speculate that obesity promotes
 vicious cycle of endothelial activation and tissue inﬂamma-
ion that contributes to adipose tissue dysfunction. Supporting
his notion, it has been shown that endothelial cells within the
dipose tissue of obese mice express higher levels of adhesion
olecules such as P-selectin, E-selectin, and intercellular adhesion
olecule 1 (ICAM-1). Moreover, administration of anti-ICAM-1
ntibody to obese mice prevents leukocyte-endothelium inter-
ctions and macrophage inﬁltration into adipose tissue [41]. In
ddition, adipose tissue inﬂammation may  also promote a state
f systemic endothelial cell activation through the endocrine
ctions of inﬂammatory adipokines such as TNF (see below),
hich could contribute to obesity-associated cardiovascular
isease.diology 63 (2014) 250–259
The adipokine concept
Accumulating evidence from animal models indicates that the
pathogenesis of obesity-related metabolic dysfunction involves
the development of a systemic, low-grade inﬂammatory state
[42,43]. Epidemiological studies have also demonstrated a connec-
tion between metabolic disease and a low-grade inﬂammation. For
example, increasing adipose mass in obese women is associated
with increased serum levels of the pro-inﬂammatory marker C-
reactive protein (CRP) [44]. Furthermore, high levels of CRP and
IL-6, are predictive of the development of type 2 diabetes [44,45]. In
contrast, weight loss leads to reductions in circulating levels of CRP
and IL-6 [46]. These ﬁndings strongly suggest that obesity is highly
associated with chronic low-grade inﬂammation, and it is believed
that this obesity-linked inﬂammatory state is due to changes in
the expression of cytokines by adipose tissue. Over the past two
decades, it has become apparent that adipose tissue is a source of
secreted immunomodulatory proteins, and that these adipokines
act as modulators of metabolic and cardiovascular processes.
While adipose tissue is mainly found in visceral and subcuta-
neous depots, it is also widely dispersed throughout the body. Other
depot sites that may  be particularly relevant in inﬂuencing cardio-
vascular disease include epicardial, perivascular, and pulmonary
adipose tissue. Whilst adipose tissue depots differ from one another
based upon their relative levels of adipokine production, obesity
will generally favor the production of pro-inﬂammatory adipokines
regardless of depot site location [47–49]. Interestingly, studies in
mice suggest that aging in the absence of diet-induced obesity
also induces the expression of proinﬂammatory adipokines, such
as TNF and IL-6 in visceral adipose tissue [50,51].
Most adipokines identiﬁed to date are pro-inﬂammatory and
they are upregulated in the obese state. Under conditions of obesity,
these adipokines function to promote metabolic and cardiovas-
cular diseases. Pro-inﬂammatory adipokines include TNF leptin,
IL-6, resistin, RBP4, lipocalin 2, IL-18, ANGPTL2, and others. Here,
as examples, we will only discuss TNF and leptin, but a partial
list of other pro-inﬂammatory adipokines and their cardiovascu-
lar actions can be found in Table 1 and Ref. [52]. In addition to
the numerous pro-inﬂammatory adipokines, adipose tissue also
secretes a smaller number of anti-inﬂammatory factors. These
factors include adiponectin, that has been the subject of intense
investigation [53,54], and SFRP5, that has been recently identiﬁed
as an adipokine with anti-inﬂammatory activities [55].
In this regard, it is difﬁcult to discern whether the increase
in cardiovascular disease associated with an adipokine imbalance
is due to a paracrine mechanism, i.e. the local release of pro-
inﬂammatory factors from epicardial or perivascular adipose tissue,
or an endocrine mechanism that is reﬂected by an increase in
serum adipokine levels. One study that shed light on this ques-
tion performed experiments involving perivascular adipose tissue
transplantation between lean and obese mice [56]. This study pro-
vided evidence that the perivascular location of adipose tissue is
critical in its ability to promote pathological vascular remodeling
and that these effects could be attributed to alterations in the levels
of adiponectin, an adipokine that will be discussed later.
Pro-inﬂammatory adipokine TNF
TNF is a pro-inﬂammatory cytokine that is predominantly
produced by monocytes/macrophages and is involved in many
inﬂammatory diseases. In 1993, TNF was  found to be induced
in adipose tissue in models of diabetes and obesity, providing the
initial evidence for a link between inﬂammation and obesity [57].
TNF expression is upregulated in the adipose tissue and the serum
of patients with obesity, whereas weight loss in obese individuals
K. Nakamura et al. / Journal of Cardiology 63 (2014) 250–259 253
Table  1
Adipokines and cardiovascular function.
Adipokine Inﬂammation Cardiovascular function(s) Reference
Leptin Pro-inﬂammatory See text
Resistin Pro-inﬂammatory Pro-atherogenic, subclinical marker of atherosclerosis, marker of heart failure, predictive of MI  and stroke risk [168–176]
RBP4 Pro-inﬂammatory subclinical marker of atherosclerosis [177–181]
Lipocalin2 Pro-inﬂammatory Unknown [182,183]
ANGPTL2 Pro-inﬂammatory Unknown [184]
TNF Pro-inﬂammatory See text
IL-6 Pro-inﬂammatory Pro-atherogenic, predictive of MI  risk [185–187]
Adiponectin Anti-inﬂammatory See text
SFRP5 Anti-inﬂammatory See text
adipolin Anti-inﬂammatory Unknown [188]
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lOmentin Anti-inﬂammatory Pro-angiogenic, inhibition of vascular in
BP4, retinol-binding protein4; ANGPT2, angiopoietin-like protein2; TNF, tumor ne
s associated with a decrease in TNF levels [58,59]. TNF levels
lso correlate with insulin resistance [60]. Mechanistically, TNF
ontributes to insulin resistance by inhibiting the activating phos-
horylation of the insulin receptor and insulin receptor substrate
 (IRS1) in muscle and adipose tissues [61]. In animal models of
besity, the inhibition of TNF leads to an enhancement of insulin
ignaling in muscle and adipose tissue [57,61,62].
TNF has numerous pathophysiological roles in the cardio-
ascular system. TNF levels are increased by acute and chronic
schemic injuries and under conditions of heart failure in humans
s well as animals [63]. As with obesity, aging is associated with a
hronic low-grade increase in TNF levels [50,64]. TNF acts on
onocytes/macrophages, vascular endothelial cells, and smooth
uscle cells to induce the expression of many pro-inﬂammatory,
ro-coagulant, and proliferative genes, contributing to atheroscle-
osis development in animal models [63,65–69]. In vascular smooth
uscle cells, TNF induces migration, proliferation, and apoptosis
70–72], which are cellular processes of major relevance in vascu-
ar pathologies. TNF also induces the rapid expression of adhesion
olecules such as E-selectin, vascular cell adhesion molecule-1,
nd ICAM-1 in endothelial cells [63,73].
TNF can have deleterious or beneﬁcial effects on the heart in
odels of ischemia-reperfusion injury and heart failure depend-
ng on the amount of TNF and the duration of exposure [63,74].
tudies aimed at investigating the effects of TNF neutralization
or the treatment of cardiac disease have led to inconsistent results
n experimental models and clinical trials. Some, but not all, animal
tudies have demonstrated that TNF neutralization or blockade of
NF receptor (TNFR) can attenuate myocardial damage in animal
odels of ischemia/reperfusion and heart failure [63]. In contrast,
ost clinical studies have failed to document the efﬁcacy of TNF
ntagonists [63]. The potential reasons for these discrepant ﬁnd-
ngs are manifold. Contributing to this complexity, TNF exerts its
ffects via two  different receptors, TNFR1 and TNFR2, which exhibit
ifferent patterns of expression and induce distinct signaling path-
ays and cellular processes. TNFR1 is constitutively expressed in
ost cell types except erythrocytes, whereas expression of TNFR2
s highly regulated and is typically higher in immune cells [75,76].
oth the pro-inﬂammatory and the proapoptotic actions of TNF
re largely mediated through TNFR1. In contrast, TNFR2 mediates
he activation of the protective JAK/STAT3 pathway and is believed
o promote tissue repair and angiogenesis [63,76].
ole of leptin in metabolic and cardiovascular disease
The adipokine leptin is the product of the obese gene (ob),
hat was identiﬁed in ob/ob mice through positional cloning
77]. Leptin regulates feeding behavior, and mice that lack lep-
in show hyperphagia, obesity, and insulin resistance. The delivery
f leptin to ob/ob mice reverses these phenotypes [78]. Notably,
eptin has been shown to be effective at improving metabolication, subclinical marker of atherosclerosis [189,190]
 factor; IL, interleukin; MI,  myocardial infarction.
dysfunction in patients with lipodystrophy or congenital leptin
deﬁciency [79,80]. However, circulating leptin levels typically cor-
relate with adipose tissue mass, and obese humans and rodents
have elevated levels of leptin without the expected anorexic
responses [78], suggesting that leptin resistance is common in obe-
sity. A number of mechanisms may  contribute to leptin resistance.
The anorexic effects of leptin result from its actions in the hypo-
thalamus, which are mediated by its binding to the leptin receptor
b (LRb) and the activation of JAK2/STAT3 signaling. In obesity, this
signaling pathway is blocked through different mechanisms, lead-
ing to leptin resistance. One of the major cellular mechanisms
contributing to this phenomenon is the STAT3-mediated induction
of the inhibitory suppressor of cytokine signaling 3 (SOCS3) protein,
which binds the phosphorylated Tyr985 residue in LRb, impairing
leptin-induced signaling [81,82]. Conclusive evidence from ani-
mal  studies supports a primary role for SOCS3 in leptin resistance
[83,84]. Additional mechanisms may  include LRb binding to the
tyrosine phosphatase SHP-2, and activation of the tyrosine phos-
phatase PTP1B, which dephosphorylates Jak2 and thus diminishes
LRb signaling (reviewed in [85]). In addition, it has been suggested
that obesity-induced endoplasmic reticulum stress in the hypothal-
amus also plays a central role in leptin resistance [86].
Leptin is structurally similar to the helical cytokine family that
includes IL-2. Inﬂammatory stimuli increase leptin levels in adi-
pose tissue and in serum [87] and leptin acts on multiple types of
immune cells, such as monocytes/macrophages, neutrophils, and
T cells, to promote the release of inﬂammatory cytokines [88–91].
In T cells, leptin speciﬁcally increases the production of TH1-type
cytokines, and suppresses production of the TH2-type cytokine IL-4
[88], thereby polarizing T cells toward a TH1 cell phenotype. Con-
sistent with these observations, leptin deﬁciency protects against
liver damage in models of T cell-mediated hepatitis and autoim-
mune encephalomyelitis [88,92,93]. Thus, it is generally accepted
that leptin acts as a pro-inﬂammatory adipokine.
Numerous studies have indicated that leptin plays an important
role in cardiovascular diseases. In humans, circulating leptin levels
are increased after myocardial infarction [94]. Similarly, leptin lev-
els are also increased in heart failure patients independent of body
mass [95], and mechanical unloading reverses this increase [96].
Leptin-deﬁcient mice display greater cardiac hypertrophy [97],
increased mortality in a model of viral myocarditis [98], and greater
cardiac remodeling in response to chronic ischemic injury [99].
Leptin receptor deﬁciency also leads to a reduction in ischemia-
induced revascularization that is associated with the impaired
induction of angiogenesis-regulatory factors in the ischemic tissue
[100]. In many of these cases, it has been shown that leptin repletion
can reverse the deleterious effects of leptin deﬁciency. However, it
is difﬁcult to ascertain whether leptin depletion or repletion has a
direct impact on these changes in cardiovascular function because
these manipulations also affect feeding behavior, adipose tis-
sue mass, and numerous systemic metabolic properties. Whereas
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eptin can activate protective JAK-STAT and AMPK signaling path-
ays in cardiovascular tissues, the interpretation of experimental
tudies on leptin that employ ob/ob mice or diet-induced obese
ice are difﬁcult to interpret due to secondary metabolic defects
hat result from hyperphagia (e.g. hyperglycemia, hyperinsuline-
ia, insulin resistance) or the development of leptin resistance,
espectively. Therefore, studies of cardiovascular disease in mice
here the leptin receptor is conditionally ablated in speciﬁc car-
iac, vascular, or immune cell types may  be required to deﬁnitely
ddress these issues.
he anti-inﬂammatory adipokine adiponectin
Adiponectin (also known as ACRP30, AdipoQ, and apM1)
as identiﬁed as an adipocyte-speciﬁc adipokine approximately
5 years ago [101–103]. Adiponectin typically circulates at
igh levels (3–30 g/ml) in the blood [104], and is markedly
ownregulated in obese human subjects. Furthermore, plasma
diponectin level is a good predictor of the risk of type 2 dia-
etes [105,106]. Adiponectin is synthesized at highest levels by
unctional adipocytes found in lean organisms but its expression is
ownregulated in the dysfunctional adipocytes that are associated
ith obesity. Consistent with this notion, adiponectin expression
y adipocytes is inhibited by pro-inﬂammatory cytokines, hypoxia,
nd oxidative stress [53,105,106], conditions associated with the
dipose tissue milieu of obese organisms.
Evidence from experimental models indicates that adiponectin
rotects against obesity-linked metabolic disease. The acute
dministration of adiponectin leads to an improvement in
etabolic parameters in a mouse model of obesity [107].
onversely, adiponectin-deﬁcient mice develop greater insulin
esistance when placed on a high calorie diet [108,109], whereas
he transgenic overexpression of adiponectin in ob/ob mice
mproves metabolic parameters independently of weight loss
110]. The beneﬁcial effects of adiponectin on insulin sensitiv-
ty appear to be mediated in part by its ability to activate AMPK
ignaling axis in metabolically important tissues [111,112]. AMPK
ctivation by adiponectin is thought to involve its interaction with
he cell surface receptors adiponectin receptor 1 and adiponectin
eceptor 2 (AdipoR1 and AdipoR2, respectively) [113–115]. In addi-
ion, studies suggest that the actions of adiponectin may  also be
ediated through additional receptors including PAQR3 (renamed
dipoR3) [116], AdipoRX [117], and T-cadherin [118].
Many lines of evidence show that adiponectin has anti-
nﬂammatory functions. Plasma adiponectin levels are negatively
orrelated with patient CRP levels [104], and adiponectin-deﬁcient
ice have higher levels of TNF in adipose tissue and blood [108].
espite morbid obesity, transgenic overexpression of adiponectin
n ob/ob mice leads to marked improvement in glucose metabolism,
hich is accompanied by reductions in macrophage inﬁltration and
NF expression in adipose tissue [110]. Adiponectin-mediated
odulation of macrophage phenotype contributes to its role in
ontrolling inﬂammation. Macrophages isolated from adiponectin-
eﬁcient mice show increased expression of pro-inﬂammatory
1 markers and decreased expression of anti-inﬂammatory M2
arkers [119]. Conversely, the overexpression of adiponectin in
ice stimulates macrophage M2  marker expression. Adiponectin
nhibits the transformation of macrophages into foam cells by
educing intracellular cholesteryl ester content [120]. Adiponectin
lso inhibits Toll-like receptor-mediated nuclear factor-B activa-
ion and stimulates production of the anti-inﬂammatory cytokine
L-10 by macrophages [121,122]. Given the importance of TNF
xpression and macrophage inﬁltration in adipose tissue dys-
unction [13,14,57], the ability of adiponectin to suppress thesediology 63 (2014) 250–259
pro-inﬂammatory events may  be an important feature in its ability
to prevent obesity-associated metabolic dysfunction.
Adiponectin is structurally similar to the collectin family of pro-
teins that include complement factor C1q and surfactant proteins
A and D. Similar to these abundantly expressed collectin proteins,
adiponectin can form high molecular mass oligomers through its
ability to multimerize via interactions through its collagen-like
domain [53,105]. A property shared by many collectin proteins is
their ability to bind to apoptotic cells and facilitate their uptake by
macrophages, a feature that is also exhibited by adiponectin [123].
Macrophages in adiponectin-deﬁcient mice display a reduced abil-
ity to clear apoptotic debris when challenged by an overload of
dead cells. Because phagocytosis of early apoptotic cells will pro-
mote an M2-like phenotype in macrophages [124], these data
suggest adiponectin’s collectin-like function contributes to its anti-
inﬂammatory actions. Finally, it should be noted that adiponectin
levels are elevated in autoimmune and chronic inﬂammatory dis-
eases [125]. While the molecular basis for adiponectin upregulation
under these conditions is unknown, it may  represent a compen-
satory response because adiponectin has been shown to ameliorate
auto-immunity in a mouse model of lupus [126,127].
Cardiovascular effects of adiponectin. Low serum levels of
adiponectin have been associated with coronary artery disease
[128], hypertension [129], left ventricular hypertrophy [130], and
a greater risk of myocardial infarction [131]. Numerous exper-
imental studies have shown that adiponectin exerts protective
actions on cardiovascular cell types including vascular endothelial
cells, smooth muscle cells, and cardiac myocytes, and adiponectin-
deﬁcient mice display worse outcomes in various models of
cardiovascular disease. Importantly, mouse models of adiponectin-
deﬁciency display normal body and fat mass and normal metabolic
parameters when fed a normal chow diet. Thus, the cardiovas-
cular actions of adiponectin can be studied independently of its
metabolic regulatory effects.
Adiponectin has been shown to exert many vasculoprotec-
tive and angiogenic properties. Studies with adiponectin-deﬁcient
mice have demonstrated that adiponectin promotes revascu-
larization of ischemic limbs [132,133], and protects against
cerebral ischemia-reperfusion [134]. Furthermore, adiponectin
inhibits experimental injury-induced neointimal hyperplasia
[135]. Adiponectin-deﬁcient mice also develop enhanced salt-
induced hypertension due in part to a reduction of endothelial
nitric oxide synthase (eNOS) activity [136], and display impaired
endothelial cell-dependent vasodilatory responses when fed an
atherogenic diet [137]. Finally, some studies, but not all, have
shown that adiponectin overexpression inhibits atherosclerotic
lesion formation, whereas adiponectin-deﬁciency leads to aug-
mented atherosclerosis [138–141]. Mechanistically, many of these
protective actions of adiponectin are linked to its beneﬁcial effects
on endothelial cell function, which are mediated to a great extent
by its ability to stimulate NO production through AMPK-dependent
activation of eNOS [142–144]. In addition, adiponectin induces
the expression of PGI2–an autacoid that promotes vascular func-
tion [145]–and prevents TNF-induced endothelial cell activation
[146,147]. Furthermore, adiponectin has been shown to inhibit pro-
liferation and migration of vascular smooth muscle cells through
direct inhibition of PDGF-BB [148], and to promote the differentia-
tion of vascular smooth muscle cells via repression of mammalian
target of rapamycin complex 1 (mTORC1) and FoxO4 [149].
Various studies have evaluated adiponectin’s actions on the
heart. Adiponectin inhibits pressure overload or angiotensin II-
induced cardiac hypertrophy, at least in part, through its ability to
activate AMPK signaling in myocytes [132,150]. Adiponectin pro-
tects the heart from ischemic reperfusion injury [151,152], and it
has been shown to be protective in models of systolic and diastolic
heart failure [153,154].
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While AdipoR1 and AdipoR2 are widely accepted as the main
eceptors accountable for the metabolic actions of adiponectin
113,114], few studies have investigated adiponectin receptors in
ardiovascular tissues. In this regard, T-cadherin, a GPI-anchored
diponectin-binding protein [118], was recently shown to be
ssential for the cardioprotective and pro-revascularization actions
f adiponectin [155,156]. T-cadherin is highly expressed in the
lasma membrane of heart, skeletal muscle, and vascular tis-
ue [157], where it co-localizes with adiponectin [155,156]. Of
ote, T-cadherin-deﬁcient mice phenocopy adiponectin-deﬁcient
ice in experimental models of chronic and acute cardiac injury
155] and chronic limb ischemia [156], strongly supporting the
ole of T-cadherin in mediating the effects of adiponectin in
he cardiovascular system. While T-cadherin lacks an intracel-
ular domain and thus is unlikely to have a direct effect on
ntracellular signaling, it has been proposed to be essential for
he recruitment of adiponectin to cardiovascular tissues. Suppor-
ing this notion, adiponectin is absent from the heart, vascular
ndothelium, and skeletal muscle in T-cadherin-deﬁcient mice
155,156,158]. In addition, T-cadherin-deﬁcient mice exhibit sig-
iﬁcantly elevated serum levels of adiponectin, further supporting
he impaired recruitment of adiponectin to cardiovascular tis-
ues in these mice. Conversely, adiponectin-deﬁcient mice have
educed tissue expression of T-cadherin suggesting a regulatory
xis between these proteins [155,156,158].
frp5
A recent study has identiﬁed Sfrp5, a soluble modulator of Wnt
roteins, as an adipokine with anti-inﬂammatory properties that
rotects against metabolic dysfunction [55]. Sfrp5 is expressed at
ighest levels in white adipose tissue of mice. Its expression in adi-
ose tissue is down-regulated in various models of rodent obesity
nd in the visceral adipose tissue of metabolically dysfunctional
bese patients that display crown-like structures. Sfrp5 functions
o antagonize noncanonical Wnt5a signaling. Wnt5a is upregulated
n fat depots of obese rodents and, as discussed below, it functions
o promote inﬂammatory responses involving macrophages.
Sfrp5-deﬁcient mice are metabolically normal when maintained
n a regular diet, but display impaired glucose metabolism and
ncreased fatty liver disease when fed a high caloric diet [55].
he enhanced metabolic dysfunction caused by Sfrp5-deﬁciency
s associated with an increased adipose tissue accumulation
f macrophages and increased production of pro-inﬂammatory
ytokines. Mechanistically, Sfrp5 functions to suppress Wnt5a-
ediated activation of JUN N-terminal kinase 1 (JNK1) in adipose
issue, and deletion of JNK1 in Sfrp5-deﬁcient mice reverses
he metabolic and inﬂammatory phenotypes. Thus, the increases
n obesity-induced adipose tissue inﬂammation and metabolic
ysfunction caused by overactivation of JNK1 signaling in Sfrp5-
eﬁcient mice, consistent with the well-described role for JNK1 in
egulating insulin resistance and fat inﬂammation [159–162].
The role of the Sfrp5/Wnt5a regulatory system in cardiovascular
isease is relatively unexplored, but a number of recent studies sug-
est that this may  be an interesting area of investigation. It has been
hown that Wnt5a functions as a macrophage effector molecule
hat promotes inﬂammation in response to microbial infection
ia the activation of noncanonical Wnt  signaling [163,164]. With
egard to cardiovascular actions, Wnt5a promotes inﬂammation
n endothelial cells [165], and noncanonical Wnt5a signaling has
een shown to suppress angiogenesis through the upregulation
f Flt1, an endogenous VEGF inhibitor produced by myeloid cells
166]. Finally, Wnt5a expression has been detected in mouse and
uman atherosclerotic lesions [165,167]. Thus, it is tempting to
peculate that Sfrp5 deﬁciency, as occurs in obesity, leads todiology 63 (2014) 250–259 255
runaway Wnt5a signaling favoring a chronic inﬂammatory state
that promotes cardiovascular disease. Further studies are required
to deﬁnitively address the role of Sfrp5/Wnt5a signaling in regula-
tion of obesity-linked inﬂammatory cardiovascular disorders.
Conclusions
Adipose tissues produce various adipokines that function to
regulate the microenvironment of adipose tissue and communi-
cate with the brain, heart, vasculature, liver, and muscle. These
adipokines have either pro-inﬂammatory or anti-inﬂammatory
activities, and their balance is critical in maintaining systemic
homeostasis. Obesity-induced adipose tissue dysfunction leads to
dysregulated adipokine production that has both local and systemic
effects on inﬂammatory cells. This adipokine imbalance leads to
the development of a low-grade, chronic inﬂammatory state that
contributes to the development of metabolic and cardiovascular
diseases.
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